The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abbott Laboratories' revenues will increase 2.3% and EPS will improve 8.9%.
The average estimate for revenue is $9.83 billion. On the bottom line, the average EPS estimate is $1.22.
Last quarter, Abbott Laboratories notched revenue of $9.46 billion. GAAP reported sales were 4.6% higher than the prior-year quarter's $9.04 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.03. GAAP EPS of $0.78 for Q1 were 42% higher than the prior-year quarter's $0.55 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 60.6%, 270 basis points better than the prior-year quarter. Operating margin was 18.2%, 140 basis points better than the prior-year quarter. Net margin was 13.1%, 350 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $39.83 billion. The average EPS estimate is $5.04.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,558 members out of 2,652 rating the stock outperform, and 94 members rating it underperform. Among 697 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 681 give Abbott Laboratories a green thumbs-up, and 16 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is outperform, with an average price target of $61.86.
- Add Abbott Laboratories to My Watchlist.